UI Hospitals and Clinics
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma
Participants in this study have been diagnosed with Multiple Myeloma. They previously participated in the main study and are now being asked to be in this substudy. Participants are being asked for additional blood samples. There will be 7 separate draws about a teaspoon size each. These samples will be used to determine the amount of denosumab in the blood.
Karen Parrott, 319-353-6347
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.